tapebrief
GL · Q4 2025
Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

GL · Q1 2026 Earnings

Globe Life

Reported April 22, 2026

30-second summary

Globe Life printed $3.43 non-GAAP EPS on $1.56B revenue (+5.3% YoY) and raised the FY2026 EPS midpoint by another $0.35 to $15.65 — the second consecutive $0.35 midpoint raise in two quarters. Underneath the headline raise, the FY2026 life premium growth guide was cut to 3–3.5% (from 4–4.5%) and total premium guide narrowed to ~7% (from 7–8%) — quiet trims on the volume side that get masked by margin expansion (life UW margin band raised 50bps to 42–45%) and a $25M buyback raise. Health is doing the heavy lifting: +13% YoY premium growth led by United American +22%, and the FY2026 health premium upper bound was lifted to 17%.

Headline numbers

EPS

Q1 FY2026

$3.43

Revenue

Q1 FY2026

$1.56B

+5.3% YoY

Key financials

Q1 FY2026
MetricQ1 FY2026YoYQ4 FY2025QoQ
Revenue$1.56B+5.3%$1.52B+2.6%
EPS$3.43—$3.39+1.2%

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

MetricPeriodGuideYoY
Administrative expenses as % of premiumFY2026approximately 7.3%—
Required interest growthFY2026around 4%—
Excess investment income growthFY2026between 4% and 4.5%—
Long-term investment yieldFY2026between 5.45% and 5.5%—
Fixed maturity portfolio yieldFY2026around 5.3%—

Changes to prior guidance

MetricPeriodPrior guideNew guideΔResult
EPS (non-GAAP)
FY2026
$14.95–$15.65 (midpoint $15.30)$15.40–$15.90 (midpoint $15.65)+$0.35 at midpoint (+2.3%); range widened by $0.25Raised
Total premium revenue growth
FY2026
7% to 8%approximately 7%Midpoint narrowed from 7.5% to 7%; upper bound removedLowered
Life premium revenue growth
FY2026
4% to 4.5%between 3% and 3.5%-1.0 to -0.5 percentage points; midpoint reduced from 4.25% to 3.25%Lowered
Health premium revenue growth
FY2026
14% to 16%between 14% and 17%+1 percentage point at upper end; range raised from 14–16% to 14–17%Raised
Life underwriting margin as % of premium
FY2026
41.5% to 44.5%between 42% and 45% (normalized, excluding Q3 assumption updates)+0.5 percentage points at lower bound; +0.5 at upper bound; range shifted upward 0.5ptsRaised
Net investment income growth
FY2026
3% to 4%around 4%+0.5 to +1.0 percentage points; lower bound raised from 3% to ~4%Raised

Reaffirmed unchanged this quarter: Health underwriting margin as % of premium (between 23% and 27%)

Segment performance

Q1 FY2026
SegmentQ1 FY2026YoY
Life Insurance$0.853B+3.0%
Health Insurance$0.417B+13.0%
American Income Life Division$0.49B+5.0%
Liberty National Division$0.147B+2.0%
Family Heritage Division$0.123B+10.0%
Direct to Consumer Division$0.265B—
United American Division$0.194B+22.0%

Capital & returns

Q1 FY2026
SegmentQ1 FY2026
Net Operating Income ROE14.0%
Net Income ROE17.9%
Book Value per Share$77.03
Book Value per Share (ex-AOCI)$98.56

Other KPIs

Q1 FY2026
SegmentQ1 FY2026
Net Operating Income per Share$3.43
Life Insurance Underwriting Margin$349.1 million
Health Insurance Underwriting Margin$94.5 million
Life Net Sales Growth6%

Management tone

Q2 FY2025 mortality-tailwind reaffirmation → Q3 FY2025 multi-year confidence signal → Q4 FY2025 segment-level disclosure escalation → Q1 FY2026 normalized-run-rate codification.

The normalization math is now the headline framing, not a footnote. Three quarters ago "normalized EPS growth" was an analyst question; two quarters ago it was a disclosed figure; one quarter ago it was used to defend the FY2026 initiation; this quarter it anchors the entire narrative — management opened with the seven-of-eight quarters of double-digit NOI growth print and explicitly published an 11.5% three-year CAGR. The quote: "normalized EPS growth, which removes the impact of assumption updates in both 25 and 26, is approximately 11%. At the midpoint of our guidance, the projected three-year compound annual growth rate of normalized EPS is 11.5%." Management is consciously trying to move analyst conversation from "what's the next quarter's beat" to "what's the compounding rate" — a structural multiple-defense argument.

AI moved from disclosed initiative to embedded margin assumption with named targets. Q4 FY2025 was the portfolio-review framing (which tech names had AI-displacement risk). Q1 FY2026 inverts the lens entirely: AI is now an internal margin lever, with the FY2026 admin expense ratio (7.3% of premium) sized as a starting point that moves "closer to 7% over the next few years." That's a quantified ~30bps multi-year operating leverage call sitting inside the EPS framework. The shift from "we're studying it" to "it's in our 2026 plan and will compress further" is the kind of language that doesn't get walked back lightly.

American Income shifted from cautious agent-count framing to explicit compensation surgery. Q3 FY2025 emphasized hires; Q4 FY2025 acknowledged turnover "exceeded expectations" and announced manager-incentive changes; Q1 FY2026 makes the timing explicit: "at the beginning of the second quarter, we have implemented compensation adjustments for our middle management team that is designed to emphasize new agent recruiting and retention of new agents. We expect these adjustments to have a positive impact on our overall agent count during the second half of this year." The guide is now low-single-digit agent count growth (not the Q4 FY2025 framing of "slightly slower than sales growth by design"). Combined with the life premium guide cut, this reads as management acknowledging the 2025 agent-count weakness has not fully arrested.

Life margin commentary stepped from "favorable mortality" to "setting from a new higher base." Q3 FY2025 introduced normalized 41.5% as the run-rate; Q4 FY2025 widened the FY2026 band to 41.5–44.5%; this quarter the band is raised 50bps to 42–45% and management telegraphed that if favorable mortality persists, additional assumption updates are possible. The quote: "that means that we're setting our new long-term assumption at a higher margin, right? So we should have earnings on the book of business overall at a little bit higher level on a go-forward basis." This is the third consecutive quarter that the implied normalized margin floor has stepped up.

Health margin framing got more granular and slightly more cautious on UA. The new disclosure that United American Q2–Q4 margins will average ~10% (vs FY 8–9%) implies Q1 ran in the low single digits, deeper than the prior Q4 FY2025 "below 10%" telegraph. Combined with the explicit $65M of approved MedSupp rate increases landing primarily in Q2–Q4, this is management protecting the full-year band rather than upgrading it — note that the health UW margin range was reaffirmed at 23–27%, not raised.

Recurring themes management leaned on this quarter:

Favorable mortality trends supporting assumption updates and margin expansionAI-driven operational efficiency with expense ratio compression expected over next few yearsStrong health premium growth driven by Medicare Advantage to Medicare Supplement migrationResiliency of target customer base despite macro headwinds and elevated lapse rates in early policy yearsAgent count stabilization at American Income through compensation structure recalibration focused on recruitingLead generation and conversion improvement enabling increased advertising spend across agency and DTC channels

Risks management surfaced:

Elevated lapse rates at American Income in first-year policies relative to recent experience amid consumer affordability stressLapse rate environment expected to remain elevated in 2026 versus pre-pandemic due to economic stress on policyholdersDirect-to-consumer channel subject to increased competitive pressure from new AI-enabled entrants with lower barriers to entryHigh comparables in United American Q4 2025 sales creating headwind for growth continuation in Q4 2026Potential for continued lapse rate fluctuations tied to macroeconomic conditions affecting working-class Americans

Answers to last quarter's watch list

DTC life premium prints positive YoY in Q1 FY2026. Did not print positive. DTC premium remained slightly negative YoY, still not inflected for the second consecutive quarter. The +1% inflection management telegraphed three quarters ago is still pending. With overall life net sales +6% in Q1, the premium-to-sales gap is widening rather than closing. Status: Continue monitoring
Q1 FY2026 health UW margin trough depth. Health UW margin was $94.5M on $417M of health premium — ~23% of premium, at the low end of the 23–27% FY band, as telegraphed. The new United American disclosure (Q2–Q4 average ~10% margin vs FY average 8–9%) implies the UA Q1 margin ran in the low-to-mid single digits — a deep trough but consistent with prior commentary. Health UW margin band was reaffirmed, not lowered. Status: Resolved positively (trough was as advertised; FY band held)
American Income producing agent count trajectory. Management disclosed Q1 average producing agent count of 11,064 (-4% YoY) and guided FY2026 to "low single-digit growth" — a step down from the Q4 FY2025 framing of "slightly slower than sales growth" and accompanied by Q2 compensation adjustments aimed at recruiting and retention. The combination of a life premium guide cut (4–4.5% → 3–3.5%) and the more cautious agent-count framing suggests the 2025 weakness has not fully reversed. Status: Resolved negatively (trajectory weaker than the Q4 FY2025 framing implied)
Bermuda reciprocal-jurisdiction approval cadence. Management reiterated a "second quarter" filing for the reciprocal jurisdiction — implying the regulatory process is progressing on the mid-2026 timeline management telegraphed in Q4 FY2025. No accelerant; no slippage signal. Zero Bermuda benefit remains in the 2026 plan. Status: Continue monitoring
FY2026 EPS guide trajectory. Raised. Midpoint +$0.35 to $15.65 — identical magnitude to the Q4 FY2025 raise, making this the second consecutive raise in two quarters. Two-quarter cumulative midpoint uplift of $0.70 (+4.7% from Q3 FY2025 initiation midpoint). Status: Resolved positively
United American 2026 sales trajectory vs. flat guide. UA premium grew +22% YoY in Q1 and net health sales more than doubled to $62M from $28M — well above the "flat" framing management used last quarter. The FY2026 health premium upper bound was raised to 17% specifically to accommodate UA strength. The 2025 doubling has not pulled forward demand to the extent management feared. Status: Resolved positively

What to watch into next quarter

Does life premium accelerate above the new 3–3.5% guide? Q1 printed +3% — bottom of the band. A Q2 print at or below 3% would be the first signal that the 100bps midpoint cut still wasn't conservative enough; +4% or better would suggest management front-loaded conservatism after the agent-count weakness.

DTC life premium finally turns positive YoY. Two consecutive slightly negative quarters with overall life net sales +6% means the channel sales-to-premium gap is widening. A Q2 print at or below 0% means the channel has stalled below the inflection point; +1% or better validates the marketing reinvestment thesis that began in Q2 FY2025.

American Income agent count print in Q2 FY2026. Management said Q2 compensation adjustments target H2 agent-count growth. A still-negative Q2 print would be expected (the changes were just implemented); a flat-to-positive Q2 with management reiterating H2 acceleration would validate the surgery. Anything worse than the Q1 FY2026 -4% YoY would call the FY2026 life premium guide into question again.

Normalized life UW margin sustains at or above 41.5%. The FY2026 guide of ~41% midpoint normalized depends on the current trend holding. A Q2 normalized print below 41% would crack the multi-quarter step-up narrative.

Bermuda reciprocal-jurisdiction filing progress in Q2 FY2026. A confirmation that the Q2 filing was made on schedule keeps the 2027 cash-flow uplift on track; any slippage commentary pushes the annual run-rate into 2028.

United American Q2 margin lands at ~10% as guided. UA Q2–Q4 averaging 10% is the math underpinning the reaffirmed 23–27% health UW margin band. A Q2 UA margin materially below 10% would put the full-year health margin band under pressure even as health premium growth accelerates.

Third consecutive FY2026 EPS midpoint raise in Q2 FY2026. Two $0.35 raises in a row is unusual; a third would either signal management is materially under-guiding or that the normalized mortality tailwind is bigger than the 41% normalized framing implies. A hold at $15.65 midpoint would suggest the mortality tailwind is now fully reflected.

Sources

  1. Globe Life Q1 FY2026 earnings release — https://www.sec.gov/Archives/edgar/data/320335/000032033526000143/q1fy2026earningsrelease.htm
  2. Globe Life Q1 FY2026 earnings call prepared remarks (Frank Svoboda, Tom Kalmbach, Matt Darden — guidance commentary)
  3. Globe Life Q1 FY2026 earnings call Q&A (Kligerman/TD Cowan on assumption-update durability; Sington/JP Morgan on MedSupp anti-selection)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.